B cell chronic lymphocytic leukaemia cells have reduced capacity to upregulate expression of MHC class I in response to interferon-γ

Pathology

Volumn 36, Issue 1, 2004, Pages 69-76

  Juffs, Helen ^a   Fowler, Nina ^a   Saal, Russell ^b   Grimmett, Karen ^b   Beasley, Shannon ^a   O'Sullivan, Brendan ^a   Frazer, Ian ^a   Gill, Devinder ^b   Thomas, Ranjeny ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Antigen presentation; B CLL; Human; MHC class I; TAP

Indexed keywords

GAMMA INTERFERON; ISOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA;

AGED; ALLELE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 1242284400     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/00313020310001644499     Document Type: Article

References (38)

1. Kalo K, Cantwell MJ, Sharma S, et al. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998; 101: 1133-41.
2. Kipps TJ. Chronic lymphocytic leukemia. Curr Opin Hematol 2000; 7: 223-34.
3. Campoli M, Chang CC, Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 2002; 20 Suppl 4: A40-5.
4. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000; 21: 455-64.
5. Traversari C, Meazza R, Coppolecchia M, et al. IFN-gamma gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer. Gene Ther 1997; 4: 1029-35.
6. Fujimaki H, Hikawa N, Nagoya M, et al. IFN-gamma induces expression of MHC class I molecules in adult mouse dorsal root ganglion neurones. Neuroreport 1996; 7: 2951-5.
7. Wierda WG, Cantwell MJ, Woods SJ, et al. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000; 96: 2917-24.
8. Cromme FV, Airey J, Heemels MT, et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994; 179: 335-40.
9. Keating PJ, Cromme FV, Duggan-Keen M, et al. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 1995; 72: 405-11.
10. Korkolopoulou P, Kaklamanis L, Pezzella F, et al. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer 1996; 73: 148-53.
11. Khanna R, Burrows SR, Moss DJ, et al. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies. J Virol 1996; 70: 5357-62.
12. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177: 265-72.
13. Crucian BE, Moscinski LC, Androlewicz M, et al. Assessment of intracellular TAP-1 and TAP-2 in conjunction with surface MHC class I in plasma cells from patients with multiple myeloma. Br J Haematol 1997; 98: 426-32.
14. Boyum A. Isolation of mononuclear cells and granulocytes from human blood: isolation of mononuclear cells by one centrifugation and of sedimentation at Ig. Scan J of Clin and Lab Invest 1968; 21(897): 77.
15. Rosenberg SA, Lipsky PE. Monocyte dependence of pokeweed mitogen-induced differentiation of immunoglobulin-secreting cells from human peripheral blood mononuclear cells. J Immunol 1979; 122: 926-31.
16. van Endert PM, Tampe R, Meyer TH, et al. A sequential model for peptide binding and transport by the transporters associated with antigen processing. Immunity 1994; 1: 491-500.
17. Sander B, Andersson J, Andersson U. Assessment of cytokines by immunofluorescence and the paraformaldehyde-saponin procedure. Immunol Rev 1991; 119: 65-93.
18. Sambrook J, Fritsch EF, Maniatis T. Analysis and cloning of eukaryotic genomic DNA. In: Molecular Cloning: a laboratory manual. Nolan C, Ford N, Ferguson M, editors. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1992; 16-19.
19. Powis SH, Tonks S, Mockridge I, et al. Alleles and haplotypes of the MHC-encoded ABC transporters TAP1 and TAP2 [published erratum appears in Immunogenetics 1993;37(6):480]. Immunogenetics 1993; 37: 373-80.
20. Cromme FV, van Bommel PF, Walboomers JM, et al. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer 1994; 69: 1176-81.
21. Evans M, Borysiewicz LK, Evans AS, et al. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol 2001; 167: 5420-8.
22. Ritz U, Momburg F, Pilch H, et al. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 2001; 19: 1211-20.
23. Zheng P, Guo Y, Niu Q, et al. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature 1998; 396: 373-6.
24. Maeurer MJ, Gollin SM, Martin D, et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 1996; 98: 1633-41.
25. Johnsen AK, Templeton DJ, Sy M, et al. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol 1996; 163: 4224-31.
26. Seliger B, Dunn T, Schwenzer A, et al. Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP and MHC class I expression and their upregulation by IFN-gamma. Scand J Immunol 1997; 46: 625-32.
27. Nouri AM, Smith S, Oliver TR, et al. Comparative expression of major histocompatibility complex (MHC) antigens on CD5+ and CD5- B cells in patients with chronic lymphocytic leukaemia (CLL). Eur J Cancer 1998; 34: 1618-22.
28. Krackhardt A, Trojan A, Gribben J. Generation of autologous T cell responses against CLL cells: Implications for immunotherapy. Blood 1999; 94: 601a.
29. Le Morvan C, Cogne M, Troutaud D, et al. Modification of HLA expression on peripheral lymphocytes and monocytes during aging. Mech Ageing Der 1998; 105: 209-20.
30. Gobin SJ, Keijsers V, van Zutphen M, et al. The role of enhancer A in the locus-specific transactivation of classical and nonclassical HLA class I genes by nuclear factor kappa B. J Immunol 1998; 161: 2276-83.
31. van den Elsen PJ, Gobin SJ. The common regulatory pathway of MHC class I and class II transactivation. Microbes Infect 1999; 1: 887-92.
32. van den Eisen PJ, Gobin SJ, van Eggermond MC, et al. Regulation of MHC class I and II gene transcription: differences and similarities. Immunogenetics 1998; 48: 208-21.
33. Demaria S, Schwab R, Gottesman SR, et al. Soluble beta 2-microglobulin-free class I heavy chains are released from the surface of activated and leukemia cells by a metalloprotease. J Biol Chem 1994; 269: 6689-94.
34. Melillo L, Musto P, Tomasi P, et al. Serum Beta2-Microglobulin in malignant lymphoproliferative disorders. Tumori 1987; 74: 129-35.
35. Faderl S, Keating MJ, Do KA, et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 2002; 16: 1045-52.
36. Mavridis AK, Tsiara S, Makis A, et al. Interleukins, TNF-alpha and beta-2M in patients with B cell chronic lymphocytic leukemia. J Exp Clin Cancer Res 1998; 17: 445-8.
37. Molica S, Levato D, Cascavilla N, et al. Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol 1999; 62: 117-22.
38. Hallek M, Wanders L, Ostwald M, et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 1996; 22: 439-47.